Life Science Intelligence

75% of MedTech Startups Fail.
Most of Those Failures Are Predictable.

Physician and BME-Led. Data-Driven.

Vantage identifies the clinical, regulatory, and commercial risks that standard due diligence misses — across medical devices, therapeutics, biologics, diagnostics, and digital health.

Quick Score: $2,500 View Pricing
24–48h
Score turnaround
98%
Risk concordance
2,000+
Companies benchmarked

Not sure where to start?

Select your role to see solutions tailored to you

Startup Founder

Building a medical device or therapeutic

VC / Angel Investor

Screening healthcare deals for investment

PE Healthcare

Evaluating platform or add-on acquisitions

Corporate M&A

Assessing strategic acquisition targets

Technology Transfer Office

Commercializing university innovations

Incubator / Accelerator

De-risking portfolio companies

Batch Pipeline Screening

Score Your Entire Pipeline in Days

Watch Vantage transform an unscored pipeline into ranked, actionable intelligence

Vantage Deal Flow
8 Companies Awaiting analysis...
Pipeline Submitted — Scoring in Progress
CompanyVerticalStageScoreStatus
8
Screened
3
Proceed
3
Monitor
2
Pass
Proceed to Full DD
Monitor / Conditional
Pass
48 hours
Total turnaround
$20,000
Total cost (8 × $2,500)
$2.4M+
Advisory fees avoided
Learn More About Deal Flow Evaluation
150+
Assessments Delivered
8
Life Science Verticals
2,000+
Companies Benchmarked
24–48h
Turnaround
98%
Risk Concordance

Comprehensive Coverage

Life Science Product Categories

Vantage handles any product type across regulatory pathways, manufacturing models, and clinical stages.

Medical Devices

510(k), PMA, De Novo pathways. Reimbursement, clinical positioning, competitive landscape.

Pharmaceuticals

NDA/ANDA approvals. CMC assessment, patent landscapes, market exclusivity analysis.

Biologics

BLA approvals, biosimilars, cell & gene therapy. Manufacturing risk and manufacturing readiness.

Diagnostics

IVD/LDT clearance paths. Companion diagnostics, clinical validation, market adoption.

Digital Health

SaMD/AI-ML regulation. De novo readiness, clinical evidence strategy, reimbursement.

Therapeutics

Drug-device combos, DTx platforms. Dual regulatory pathways, manufacturing complexity.

Combination Products

OCP guidance, co-pack strategies. Regulatory assignment, labeling, manufacturing controls.

MedTech Services

Contract manufacturing, outsourced development. Partnership risk, supply chain resilience.

Depth of Analysis

See What Standard Due Diligence Misses

Our physician and engineer-led analysis penetrates layer by layer, exposing hidden risks that surface-level review cannot detect.

Most Due Diligence Stops at the Surface

Standard VC and PE due diligence relies on generalists reviewing pitch decks, financials, and team bios. They catch obvious red flags — but miss the clinical, regulatory, and engineering risks that actually kill companies post-investment.

Vantage goes four layers deep. Our physician reviews clinical viability from the perspective of someone who has sat on P&T committees deciding device adoption. Our engineer assesses manufacturing readiness from experience scaling production at billion-dollar acquirers.

The deepest layer — where clinical-technical risks intersect — is where we find the issues that surface-level diligence cannot.

01Surface
Standard Due DiligenceMBA / Finance / Legal
✓ Pitch deck ✓ Financials ✓ Cap table ✓ Team bios ✓ Market size
All clear
02Clinical
Physician-Led ReviewMD / Clinical Specialist
✓ Regulatory pathway ⚠ Clinical evidence gaps ✓ Safety profile ⚠ Adoption barriers ✓ Unmet need
2 risks found
03Technical
Engineering ReviewBME / Manufacturing
✓ IP landscape ⚠ Scale-up risk ⚠ Quality gaps ✓ Design maturity ✓ Supply chain
2 risks found
04Deep
Clinical-Technical IntersectionMD + BME Combined
✕ Reimbursement misalignment ✕ Regulatory-manufacturing conflict ⚠ Competitive timing ✕ Hidden predicate risk
3 critical risks
Clear
Risk found
Critical

Four-Tier Pricing

Pick the depth that fits the decision

Every tier is a flat fee. Start with a Quick Score, scale to deeper diligence when the decision demands it.

Triage

Quick Score

Rapid go/no-go read for screening and first-pass diligence.

$2,500
24-hour turnaround
  • 6-domain composite score
  • Band + top risk flags
  • 4-page PDF + DOCX
Start Quick Score
Founder / TTO

Full Score

Physician-reviewed deep-dive with narrative and risk priorities.

$7,500
48-hour turnaround
  • MD-reviewed report
  • 15–30 page narrative
  • Path-to-next-band plan
  • 30-min debrief
Get Full Score
Most Popular

Investor Score

IC-ready executive summary with peer anchor and deal risk matrix.

$15,000
48-hour turnaround
  • All Full Score deliverables
  • IC summary lift-out
  • Peer anchor + deal risk matrix
  • Partner voice commentary
Get Investor Score
Corporate / M&A

Corporate Score

Board-ready diligence with valuation and R&W risk map.

$25,000
48-hour turnaround
  • All Investor Score deliverables
  • Valuation + R&W risk map
  • Standalone board memo
  • 60-min strategy session
Get Corporate Score

Pipeline-wide batches? See Deal Flow for bulk Quick Score pricing (as low as $2,000/co at 20+).

Methodology, stress-tested in public

Most diligence reports describe the company. Ours scores it against the same questions a hospital P&T committee asks before formulary inclusion — and against public retrospectives on Theranos, Exactech, Pear, and Owlet, so you can see the framework run on cases everyone now agrees were knowable.

Read the public retrospectives → · See a sample report →

Our Team

MD + Engineer Partnership

Two complementary perspectives: clinical rigor and technical depth. Founded by Dr. Arvind Ravinutala (MD, physician executive) and Aswini Ravinutala (BME, biomedical engineer). Backed by physician specialists and C-suite advisors across 8+ device categories.

Dr. Arvind Ravinutala

Arvind Ravinutala

Co-Founder, Clinical Reviewer
MD | Physician Executive | Clinical Strategy

Physician leader with deep expertise in medical device development, regulatory strategy, and clinical adoption. Drives clinical rigor across all assessments.

Aswini Ravinutala

Aswini Ravinutala

Co-Founder, Technical Reviewer
BME | Biomedical Engineer | Manufacturing & Quality

Biomedical engineer with manufacturing, quality systems, and regulatory expertise. Ensures technical depth in all assessments and competitive analysis.

Ready to Move Forward?

Start with a Quick Score and see what Vantage can do for your due diligence, investment thesis, or strategic decision.

Get a Quick Score

Before you go...

Get a Quick Score for $2,500 — 24-hour turnaround across all 8 life science verticals. Know where your product stands before your next meeting.

Get My Quick Score